首页 > 最新文献

Hematology, transfusion and cell therapy最新文献

英文 中文
Hemolytic anemia due to pyruvate kinase deficiency coexistent with the alpha thalassemia trait and chronic myeloid leukemia. 丙酮酸激酶缺乏症导致的溶血性贫血与阿尔法地中海贫血症和慢性髓性白血病并存。
Pub Date : 2024-09-12 DOI: 10.1016/j.htct.2024.04.130
Nirmal Shrestha, Harshit Khurana, Renjith Verghese, Yogendra Mishra
{"title":"Hemolytic anemia due to pyruvate kinase deficiency coexistent with the alpha thalassemia trait and chronic myeloid leukemia.","authors":"Nirmal Shrestha, Harshit Khurana, Renjith Verghese, Yogendra Mishra","doi":"10.1016/j.htct.2024.04.130","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.130","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial acute myeloid leukemia due to a novel germline CEBPA pathogenic variant - a case report. 新型种系 CEBPA 致病变体导致的家族性急性髓性白血病--病例报告。
Pub Date : 2024-09-12 DOI: 10.1016/j.htct.2024.07.004
Flavia Gava, Luiz Fernando Bazzo Catto, Elvis Valera, Maristella Bergamo Francisco Dos Reis, Maria Carolina Tostes Pintão, Maria de Lourdes Chauffaille, Flavia Sacilotto Donaires Ramos, Carlos Alberto Scrideli, Lorena Lobo Figueiredo Pontes
{"title":"Familial acute myeloid leukemia due to a novel germline CEBPA pathogenic variant - a case report.","authors":"Flavia Gava, Luiz Fernando Bazzo Catto, Elvis Valera, Maristella Bergamo Francisco Dos Reis, Maria Carolina Tostes Pintão, Maria de Lourdes Chauffaille, Flavia Sacilotto Donaires Ramos, Carlos Alberto Scrideli, Lorena Lobo Figueiredo Pontes","doi":"10.1016/j.htct.2024.07.004","DOIUrl":"https://doi.org/10.1016/j.htct.2024.07.004","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of cerebrospinal fluid chimerism after hematopoietic stem cell transplantation: Case report. 造血干细胞移植后脑脊液嵌合体分析:病例报告。
Pub Date : 2024-09-11 DOI: 10.1016/j.htct.2024.04.129
Yeliz Ogret, Tarik Onur Tiryaki, Cigdem Kekik Cinar, Ipek Yonal Hindilerden, Dilek Ozden Ozluk, Meliha Nalcaci, Fatma Savran Oguz
{"title":"Analysis of cerebrospinal fluid chimerism after hematopoietic stem cell transplantation: Case report.","authors":"Yeliz Ogret, Tarik Onur Tiryaki, Cigdem Kekik Cinar, Ipek Yonal Hindilerden, Dilek Ozden Ozluk, Meliha Nalcaci, Fatma Savran Oguz","doi":"10.1016/j.htct.2024.04.129","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.129","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minor surgical procedures during immune tolerance induction in people with hemophilia A and inhibitors: results from the Brazilian Immune Tolerance (BrazIT) study cohort. 血友病 A 和抑制剂患者免疫耐受诱导期间的小型外科手术:巴西免疫耐受(BrazIT)研究队列的结果。
Pub Date : 2024-09-10 DOI: 10.1016/j.htct.2024.05.010
Ricardo Mesquita Camelo, Maíse Moreira Dias, Suely Meireles Rezende

Introduction: Surgeries are implicated in the development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) in hemophilia A individuals with immune tolerance induction (ITI) treatment being the recommended therapy to eradicate these inhibitors. We evaluated the association of surgical procedures performed during ITI and treatment outcome.

Methods: Patients were treated according to the Brazilian ITI Protocol with outcomes being defined as successful (i.e., recovered responsiveness to exogenous FVIII) and failed (i.e., unresponsiveness to exogenous FVIII thus requiring bypassing agents for bleeding control). Surgical procedures during induction therapy were managed following international recommendations.

Results: Treatment success rate was 68.7 % in 163 patients; 33 (20.2 %) were submitted to 43 (96 %) minor and two major surgeries. Personal, hemophilia, inhibitor, and treatment characteristics were similar between patients submitted to surgical procedures or not while on ITI; the success rates were 72.7 % and 67.7 % (p-value = 0.577), respectively.

Conclusion: No association was found between having a minor surgical procedure and ITI treatment outcome.

导言:手术与 A 型血友病患者体内抗因子 VIII(FVIII)中和抗体(抑制剂)的产生有关,而免疫耐受诱导(ITI)治疗是根除这些抑制剂的推荐疗法。我们评估了 ITI 期间进行的外科手术与治疗结果之间的关联:患者按照巴西 ITI 方案接受治疗,治疗结果被定义为成功(即对外源性 FVIII 恢复反应)和失败(即对外源性 FVIII 无反应,因此需要旁路药物控制出血)。诱导治疗期间的外科手术按照国际建议进行管理:结果:163 名患者的治疗成功率为 68.7%;33 人(20.2%)接受了 43 次小手术(96%)和 2 次大手术。在使用 ITI 期间是否接受手术治疗的患者的个人、血友病、抑制剂和治疗特征相似;成功率分别为 72.7 % 和 67.7 %(P 值 = 0.577):结论:小手术与 ITI 治疗结果之间没有关联。
{"title":"Minor surgical procedures during immune tolerance induction in people with hemophilia A and inhibitors: results from the Brazilian Immune Tolerance (BrazIT) study cohort.","authors":"Ricardo Mesquita Camelo, Maíse Moreira Dias, Suely Meireles Rezende","doi":"10.1016/j.htct.2024.05.010","DOIUrl":"https://doi.org/10.1016/j.htct.2024.05.010","url":null,"abstract":"<p><strong>Introduction: </strong>Surgeries are implicated in the development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) in hemophilia A individuals with immune tolerance induction (ITI) treatment being the recommended therapy to eradicate these inhibitors. We evaluated the association of surgical procedures performed during ITI and treatment outcome.</p><p><strong>Methods: </strong>Patients were treated according to the Brazilian ITI Protocol with outcomes being defined as successful (i.e., recovered responsiveness to exogenous FVIII) and failed (i.e., unresponsiveness to exogenous FVIII thus requiring bypassing agents for bleeding control). Surgical procedures during induction therapy were managed following international recommendations.</p><p><strong>Results: </strong>Treatment success rate was 68.7 % in 163 patients; 33 (20.2 %) were submitted to 43 (96 %) minor and two major surgeries. Personal, hemophilia, inhibitor, and treatment characteristics were similar between patients submitted to surgical procedures or not while on ITI; the success rates were 72.7 % and 67.7 % (p-value = 0.577), respectively.</p><p><strong>Conclusion: </strong>No association was found between having a minor surgical procedure and ITI treatment outcome.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychological aspects in young people with venous thromboembolic disease, preliminary report. 患有静脉血栓栓塞性疾病的年轻人的心理问题,初步报告。
Pub Date : 2024-09-08 DOI: 10.1016/j.htct.2024.06.007
Alejandro Godoy, N Bula Galli, Aldo Tabares

Background: The decline in the mental well-being of young adults following an episode of venous thromboembolism may be related to the uncertainty of long-term health and fear of recurrence. In recent years, post-pulmonary embolism syndrome has gained acceptance, however, less attention has been given to the psychological impact on young patients after venous thromboembolism. This study explores the prevalence, type, and severity of psychological disorders of patients following venous thromboembolism.

Methods: A retrospective observational cohort study was performed of over 18-year-old patients diagnosed with venous thromboembolism followed in the Vascular Medicine Service at Hospital Privado de Córdoba, Argentina from July 2020 to October 2021. Due to the COVID-19 pandemic, virtual interviews were conducted using two pre-established questionnaires administered by the same psychiatrist. The first questionnaire gathered personal data, clinical history, and mental health information, while the second, evaluated mood disorders using the Mini International Neuropsychiatric Interview. Patients with a positive MINI score underwent further assessment using the Hamilton Scale. Patients were considered young if ≤45 years.

Results: A total of 50 patients were assessed, 56 % were women, and 54 % were ≤45 years. Major depression was documented in 11 (22 %) patients, eight (72 %) in the younger group, and three (28 %) in the older group. Eight (16 %) patients had an anxiety disorder, four in the younger group, and ten (20 %) patients had post-traumatic stress disorder, seven (70 %) of the younger patients. Generalized anxiety disorder was identified in 20 (40 %) patients with similar proportions in both groups.

Conclusion: Psychological and emotional symptoms are common following an episode of venous thromboembolism. Post-traumatic stress disorder and depression appear to be numerically more prevalent in the young.

背景:静脉血栓栓塞症发作后,年轻人的心理健康水平会下降,这可能与长期健康的不确定性和对复发的恐惧有关。近年来,肺栓塞后综合征已被越来越多的人接受,然而,静脉血栓栓塞后对年轻患者心理影响的关注却较少。本研究探讨了静脉血栓栓塞后患者心理障碍的发生率、类型和严重程度:该研究对阿根廷科尔多瓦私立医院血管内科 2020 年 7 月至 2021 年 10 月期间诊断为静脉血栓栓塞症的 18 岁以上患者进行了回顾性队列观察研究。由于 COVID-19 大流行,虚拟访谈使用了两份预先确定的调查问卷,由同一位精神科医生进行管理。第一份问卷收集个人资料、临床病史和心理健康信息,第二份问卷则使用迷你国际神经精神病学访谈评估情绪障碍。迷你国际神经精神访谈得分呈阳性的患者将使用汉密尔顿量表进行进一步评估。年龄小于 45 岁的患者被视为年轻患者:共有 50 名患者接受了评估,其中 56% 为女性,54% 年龄小于 45 岁。11名患者(22%)患有重度抑郁症,其中8名年轻患者(72%),3名老年患者(28%)。八名患者(16%)患有焦虑症,其中四名年轻患者,十名患者(20%)患有创伤后应激障碍,其中七名年轻患者(70%)。20名(40%)患者患有广泛性焦虑症,两组比例相似:结论:静脉血栓栓塞症发作后,心理和情绪症状很常见。结论:静脉血栓栓塞症发作后,心理和情绪症状很常见,创伤后应激障碍和抑郁症似乎在年轻人中更为普遍。
{"title":"Psychological aspects in young people with venous thromboembolic disease, preliminary report.","authors":"Alejandro Godoy, N Bula Galli, Aldo Tabares","doi":"10.1016/j.htct.2024.06.007","DOIUrl":"https://doi.org/10.1016/j.htct.2024.06.007","url":null,"abstract":"<p><strong>Background: </strong>The decline in the mental well-being of young adults following an episode of venous thromboembolism may be related to the uncertainty of long-term health and fear of recurrence. In recent years, post-pulmonary embolism syndrome has gained acceptance, however, less attention has been given to the psychological impact on young patients after venous thromboembolism. This study explores the prevalence, type, and severity of psychological disorders of patients following venous thromboembolism.</p><p><strong>Methods: </strong>A retrospective observational cohort study was performed of over 18-year-old patients diagnosed with venous thromboembolism followed in the Vascular Medicine Service at Hospital Privado de Córdoba, Argentina from July 2020 to October 2021. Due to the COVID-19 pandemic, virtual interviews were conducted using two pre-established questionnaires administered by the same psychiatrist. The first questionnaire gathered personal data, clinical history, and mental health information, while the second, evaluated mood disorders using the Mini International Neuropsychiatric Interview. Patients with a positive MINI score underwent further assessment using the Hamilton Scale. Patients were considered young if ≤45 years.</p><p><strong>Results: </strong>A total of 50 patients were assessed, 56 % were women, and 54 % were ≤45 years. Major depression was documented in 11 (22 %) patients, eight (72 %) in the younger group, and three (28 %) in the older group. Eight (16 %) patients had an anxiety disorder, four in the younger group, and ten (20 %) patients had post-traumatic stress disorder, seven (70 %) of the younger patients. Generalized anxiety disorder was identified in 20 (40 %) patients with similar proportions in both groups.</p><p><strong>Conclusion: </strong>Psychological and emotional symptoms are common following an episode of venous thromboembolism. Post-traumatic stress disorder and depression appear to be numerically more prevalent in the young.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of erythrocyte alloimmunization among patients treated at a Brazilian university hospital. 评估巴西一家大学医院接受治疗的患者的红细胞同种免疫情况。
Pub Date : 2024-09-07 DOI: 10.1016/j.htct.2024.04.128
Higor Silva Contelli, Mário Cézar de Oliveira, Aline Akemi Segatti Ido, Elaine Machado Francalanci, Patrícia Oliveira da Cunha Terra, Elmiro Ribeiro Filho, Deivid William da Fonseca Batistão, Sabrina Royer

Introduction: Alloimmunization and transfusion reactions underscore the crucial role of precise immunohematological techniques to enhance safety in transfusion. This study aims to determine the frequency of alloimmunization in patients treated at a Brazilian university hospital, investigate demographic, clinical, and epidemiological characteristics of patients with positive irregular antibody screening, as well as to assess the frequency of erythrocyte antigens and anti-erythrocyte antibodies in the population.

Materials and methods: This retrospective observational study included all irregular antibody-positive patients treated at the transfusion service of Hospital de Clínicas of the Federal University of Uberlandia between January 2019 and December 2020.

Results: Of the 201 irregular antibody-positive patients, alloimmunization was more common in women (64.2%) than in men (35.8%). Blood groups A (39.8%) and O (38.8%), and Rh positive samples (69.1%) predominated, and about half (48.2%) of the patients were transfused for preoperative procedures. The most frequently found clinically significant alloantibodies were anti-D (27.2%), anti-E (15.0%), and anti-Kell (11.5%). Of the patients, 30.6% had multiple antibody associations, with anti-D and anti-C being the most common combination. Erythrocyte immunophenotyping was performed for 76 patients with the most frequent antigens detected being e (100%), c (86.8%), and C (40.8%). Among the 14 pregnant women evaluated, most were multiparous, 85.7% had anti-D as the most prevalent antibody, and had the A-negative blood type (33.3%).

Conclusion: Alloantibody screening and identification associated with erythrocyte immunophenotyping are necessary for a better understanding of the alloimmunized population, ensuring greater safety and efficacy of transfusion therapy in the hospital setting.

导言:同种免疫和输血反应凸显了精确的免疫血液学技术在提高输血安全性方面的关键作用。本研究旨在确定在巴西一所大学医院接受治疗的患者中发生同种免疫的频率,调查不规则抗体筛查阳性患者的人口学、临床和流行病学特征,以及评估人群中红细胞抗原和抗红细胞抗体的频率:这项回顾性观察研究纳入了2019年1月至2020年12月期间在乌伯兰迪亚联邦大学临床医院输血科接受治疗的所有不规则抗体阳性患者:在201名不规则抗体阳性患者中,女性(64.2%)比男性(35.8%)更容易发生同种免疫。血型以 A 型(39.8%)和 O 型(38.8%)以及 Rh 阳性样本(69.1%)为主,约半数(48.2%)患者在术前进行了输血。最常发现的具有临床意义的同种抗体是抗-D(27.2%)、抗-E(15.0%)和抗-Kell(11.5%)。其中,30.6%的患者存在多种抗体关联,抗-D 和抗-C 是最常见的抗体组合。对 76 名患者进行了红细胞免疫分型,最常检测到的抗原是 e(100%)、c(86.8%)和 C(40.8%)。在接受评估的 14 名孕妇中,大多数是多胎妊娠,85.7% 的孕妇最常见的抗体是抗 D,血型为 A 阴性(33.3%):结论:为了更好地了解异体免疫人群,有必要进行与红细胞免疫分型相关的异体抗体筛查和鉴定,以确保在医院环境中提高输血治疗的安全性和有效性。
{"title":"Assessment of erythrocyte alloimmunization among patients treated at a Brazilian university hospital.","authors":"Higor Silva Contelli, Mário Cézar de Oliveira, Aline Akemi Segatti Ido, Elaine Machado Francalanci, Patrícia Oliveira da Cunha Terra, Elmiro Ribeiro Filho, Deivid William da Fonseca Batistão, Sabrina Royer","doi":"10.1016/j.htct.2024.04.128","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.128","url":null,"abstract":"<p><strong>Introduction: </strong>Alloimmunization and transfusion reactions underscore the crucial role of precise immunohematological techniques to enhance safety in transfusion. This study aims to determine the frequency of alloimmunization in patients treated at a Brazilian university hospital, investigate demographic, clinical, and epidemiological characteristics of patients with positive irregular antibody screening, as well as to assess the frequency of erythrocyte antigens and anti-erythrocyte antibodies in the population.</p><p><strong>Materials and methods: </strong>This retrospective observational study included all irregular antibody-positive patients treated at the transfusion service of Hospital de Clínicas of the Federal University of Uberlandia between January 2019 and December 2020.</p><p><strong>Results: </strong>Of the 201 irregular antibody-positive patients, alloimmunization was more common in women (64.2%) than in men (35.8%). Blood groups A (39.8%) and O (38.8%), and Rh positive samples (69.1%) predominated, and about half (48.2%) of the patients were transfused for preoperative procedures. The most frequently found clinically significant alloantibodies were anti-D (27.2%), anti-E (15.0%), and anti-Kell (11.5%). Of the patients, 30.6% had multiple antibody associations, with anti-D and anti-C being the most common combination. Erythrocyte immunophenotyping was performed for 76 patients with the most frequent antigens detected being e (100%), c (86.8%), and C (40.8%). Among the 14 pregnant women evaluated, most were multiparous, 85.7% had anti-D as the most prevalent antibody, and had the A-negative blood type (33.3%).</p><p><strong>Conclusion: </strong>Alloantibody screening and identification associated with erythrocyte immunophenotyping are necessary for a better understanding of the alloimmunized population, ensuring greater safety and efficacy of transfusion therapy in the hospital setting.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance and safety of therapeutic erythrocytapheresis in polycythemia and hemochromatosis treatment: single centre experience. 在多血症和血色素沉着症治疗中使用治疗性红细胞透析的效果和安全性:单中心经验。
Pub Date : 2024-09-07 DOI: 10.1016/j.htct.2024.05.011
Iva Lucija Burnać, Ines Bojanić, Sanja Mazić, Marija Lukić, Branka Golubić Ćepulić

Introduction: Therapeutic erythrocytapheresis has some advantages over therapeutic phlebotomy, the standard treatment for cytoreduction in polycythemia and hemochromatosis. Erythrocytapheresis can be performed on different cell separators, each with its own characteristics. We present our experience of therapeutic erythrocytapheresis in the treatment of polycythemia and hemochromatosis with an analysis of the performance of cytoreduction, and a comparison between the characteristics of intermittent- and continuous-flow cell separators.

Material and methods: During a 20-year period, 1731 procedures were performed in 125 patients, 1634 (94.4%) with a Haemonetics MCS+ separator and 97 (5.6%) with a Spectra Optia system device. The performance of cytoreduction using the Haemonetics MCS+ separator was analysed in 442 procedures performed in 56 patients and the performance of the two apheresis devices was compared.

Results: Haemoglobin (Hb) and haematocrit (Hct) values were significantly reduced after erythrocytapheresis with the Haemonetics MCS+ device (Hb: 18.69%; Hct: 18.73%; p-values both <0.001). The reductions of Hb and Hct were significantly higher in the Haemonetics MCS+ procedure (p-value <0.001), but the Spectra Optia procedure depleted a significantly higher RBC volume (495 mL versus 442 mL) in a shorter time (18 min versus 36 min).

Conclusion: Both the Haemonetics MCS+ and Spectra Optia systems proved to be highly efficient and safe in RBC cytoreduction with short procedure times. Erythrocytapheresis reduces the frequency of necessary procedures thereby justifying its therapeutic use especially in eligible patients of working age.

导言:治疗性红细胞吸除术与治疗性抽血术相比具有一些优势,后者是多血症和血色素沉着症细胞减少的标准治疗方法。红细胞吸附可在不同的细胞分离器上进行,每种分离器都有自己的特点。我们介绍了治疗多血症和血色素沉着症的红细胞吸附疗法的经验,分析了细胞还原的效果,并比较了间歇式细胞分离器和连续式细胞分离器的特点:在20年的时间里,共为125名患者实施了1731例手术,其中1634例(94.4%)使用了Haemonetics MCS+分离器,97例(5.6%)使用了Spectra Optia系统设备。使用 Haemonetics MCS+ 分离器对 56 名患者的 442 例手术进行了细胞减少性能分析,并比较了两种血液净化设备的性能:结果:使用Haemonetics MCS+设备进行红细胞分离后,血红蛋白(Hb)和血细胞比容(Hct)值明显降低(Hb:18.69%;Hct:18.73%;P值均为结论):事实证明,Haemonetics MCS+ 和 Spectra Optia 系统都能在短时间内高效、安全地进行红细胞回收。红细胞清除术减少了必要的手术频率,因此有理由使用它进行治疗,尤其是对符合条件的工作年龄患者。
{"title":"Performance and safety of therapeutic erythrocytapheresis in polycythemia and hemochromatosis treatment: single centre experience.","authors":"Iva Lucija Burnać, Ines Bojanić, Sanja Mazić, Marija Lukić, Branka Golubić Ćepulić","doi":"10.1016/j.htct.2024.05.011","DOIUrl":"https://doi.org/10.1016/j.htct.2024.05.011","url":null,"abstract":"<p><strong>Introduction: </strong>Therapeutic erythrocytapheresis has some advantages over therapeutic phlebotomy, the standard treatment for cytoreduction in polycythemia and hemochromatosis. Erythrocytapheresis can be performed on different cell separators, each with its own characteristics. We present our experience of therapeutic erythrocytapheresis in the treatment of polycythemia and hemochromatosis with an analysis of the performance of cytoreduction, and a comparison between the characteristics of intermittent- and continuous-flow cell separators.</p><p><strong>Material and methods: </strong>During a 20-year period, 1731 procedures were performed in 125 patients, 1634 (94.4%) with a Haemonetics MCS+ separator and 97 (5.6%) with a Spectra Optia system device. The performance of cytoreduction using the Haemonetics MCS+ separator was analysed in 442 procedures performed in 56 patients and the performance of the two apheresis devices was compared.</p><p><strong>Results: </strong>Haemoglobin (Hb) and haematocrit (Hct) values were significantly reduced after erythrocytapheresis with the Haemonetics MCS+ device (Hb: 18.69%; Hct: 18.73%; p-values both <0.001). The reductions of Hb and Hct were significantly higher in the Haemonetics MCS+ procedure (p-value <0.001), but the Spectra Optia procedure depleted a significantly higher RBC volume (495 mL versus 442 mL) in a shorter time (18 min versus 36 min).</p><p><strong>Conclusion: </strong>Both the Haemonetics MCS+ and Spectra Optia systems proved to be highly efficient and safe in RBC cytoreduction with short procedure times. Erythrocytapheresis reduces the frequency of necessary procedures thereby justifying its therapeutic use especially in eligible patients of working age.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An instrument of screening criteria to assess individualized high-risk sexual behavior to be applied in the Brazilian population: translation and cross-cultural adaptation. 用于评估巴西人口个性化高风险性行为的筛查标准工具:翻译和跨文化调整。
Pub Date : 2024-09-07 DOI: 10.1016/j.htct.2024.06.009
Miriane Lucindo Zucoloto, Guilherme Galdino, Edson Zangiacomi Martinez

Background: Alternative approaches have been proposed to ensure a safe and equitable screening process for blood donation that treats all people equally, regardless of gender identity or sexual orientation. The terms 'neutral approach' and 'individualized risk assessment' have been used to describe this goal. To facilitate research and implementation of these concepts in blood donation contexts and health services in Brazil, we propose a Portuguese version of the 'for the assessment of individualized risk screening criteria' (FAIR) screening criteria.

Methods: The FAIR screening criteria are 12 questions that assess sex, sexuality, ethnicity, and the extent to which participants engaged in each targeted sexual behavior. The aim of FAIR is to reduce error while increasing reliable and accurate reporting of sexual behaviors associated with both objective and subjective estimates of infection risk. The FAIR screening criteria were translated and cross-culturally adapted using a systematic approach with standardized procedures appropriate for adapting instruments that track behaviors.

Results: A version that is appropriate for use with the Brazilian population was produced employing the following steps: expert translations, harmonization, consensus version, expert back-translation, revision, panel of experts, cognitive interviewing, and finalization.

Conclusion: The Portuguese version of FAIR was proposed, and because of its straightforward, simple language and focus on specific and frequent behaviors in some populations, it has the potential to be used in a variety of contexts involving the screening of high-risk sexual behavior in Brazil.

背景:为确保献血筛查过程安全、公平,不分性别认同或性取向,一视同仁,人们提出了一些替代方法。中性方法 "和 "个性化风险评估 "被用来描述这一目标。为了促进这些概念在巴西献血环境和医疗服务中的研究和实施,我们提出了葡萄牙语版的 "个性化风险筛查评估标准"(FAIR)筛查标准:FAIR 筛查标准由 12 个问题组成,对参与者的性别、性取向、种族以及参与每种目标性行为的程度进行评估。FAIR 的目的是减少误差,同时提高与客观和主观估计感染风险相关的性行为报告的可靠性和准确性。FAIR 筛选标准经过翻译和跨文化改编,采用了适合改编行为跟踪工具的标准化程序:结果:采用以下步骤制作了适合巴西人口使用的版本:专家翻译、协调、共识版本、专家回译、修订、专家小组、认知访谈和定稿:提出了 FAIR 的葡萄牙语版本,由于其语言简单明了,且侧重于某些人群中的特定和频繁行为,因此有可能用于巴西涉及高危性行为筛查的各种情况。
{"title":"An instrument of screening criteria to assess individualized high-risk sexual behavior to be applied in the Brazilian population: translation and cross-cultural adaptation.","authors":"Miriane Lucindo Zucoloto, Guilherme Galdino, Edson Zangiacomi Martinez","doi":"10.1016/j.htct.2024.06.009","DOIUrl":"https://doi.org/10.1016/j.htct.2024.06.009","url":null,"abstract":"<p><strong>Background: </strong>Alternative approaches have been proposed to ensure a safe and equitable screening process for blood donation that treats all people equally, regardless of gender identity or sexual orientation. The terms 'neutral approach' and 'individualized risk assessment' have been used to describe this goal. To facilitate research and implementation of these concepts in blood donation contexts and health services in Brazil, we propose a Portuguese version of the 'for the assessment of individualized risk screening criteria' (FAIR) screening criteria.</p><p><strong>Methods: </strong>The FAIR screening criteria are 12 questions that assess sex, sexuality, ethnicity, and the extent to which participants engaged in each targeted sexual behavior. The aim of FAIR is to reduce error while increasing reliable and accurate reporting of sexual behaviors associated with both objective and subjective estimates of infection risk. The FAIR screening criteria were translated and cross-culturally adapted using a systematic approach with standardized procedures appropriate for adapting instruments that track behaviors.</p><p><strong>Results: </strong>A version that is appropriate for use with the Brazilian population was produced employing the following steps: expert translations, harmonization, consensus version, expert back-translation, revision, panel of experts, cognitive interviewing, and finalization.</p><p><strong>Conclusion: </strong>The Portuguese version of FAIR was proposed, and because of its straightforward, simple language and focus on specific and frequent behaviors in some populations, it has the potential to be used in a variety of contexts involving the screening of high-risk sexual behavior in Brazil.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complex somatic mutation landscape in myeloid cells in a patient with VEXAS syndrome: First Brazilian case report. VEXAS 综合征患者髓系细胞中的复杂体细胞突变景观:巴西首例病例报告。
Pub Date : 2024-09-07 DOI: 10.1016/j.htct.2024.05.013
Fabíola Reis de Oliveira, Adriane Souza Lima, Carlos Roberto Faria, Thaise Oliveira Quaresma, Marcio M Mourani, Lauro Wichert-Ana, Paulo Louzada, Fernanda Gutierrez-Rodrigues, Neal S Young, Rodrigo T Calado
{"title":"Complex somatic mutation landscape in myeloid cells in a patient with VEXAS syndrome: First Brazilian case report.","authors":"Fabíola Reis de Oliveira, Adriane Souza Lima, Carlos Roberto Faria, Thaise Oliveira Quaresma, Marcio M Mourani, Lauro Wichert-Ana, Paulo Louzada, Fernanda Gutierrez-Rodrigues, Neal S Young, Rodrigo T Calado","doi":"10.1016/j.htct.2024.05.013","DOIUrl":"https://doi.org/10.1016/j.htct.2024.05.013","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The survivin/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2V617F cells. 存活素/XIAP抑制剂YM155可抑制JAK2V617F细胞的克隆生长并诱导其凋亡。
Pub Date : 2024-09-07 DOI: 10.1016/j.htct.2024.05.012
Jorge Antonio Elias Godoy Carlos, Keli Lima, Eduardo Magalhães Rego, Leticia Veras Costa-Lotufo, João Agostinho Machado-Neto

The central role of the control of apoptosis in the pathophysiology of Philadelphia chromosome-negative myeloproliferative neoplasms has recently been reinforced in genetic and pharmacological studies. The inhibitor of apoptosis protein family has eight members and plays an important role in apoptosis, with the most studied being survivin (BIRC5) and X-linked inhibitor of apoptosis (XIAP). YM155 is a small molecule with antineoplastic potential that has been described as a suppressant of survivin and XIAP. In the present study, BIRC5 expression was significantly increased in primary myelofibrosis patients compared to healthy donors. On the other hand, XIAP expression was reduced in myeloproliferative neoplasms patients. In JAK2V617F cells, YM155 reduces cell viability and autonomous clonal growth and induces apoptosis, cell cycle arrest, and autophagy. HEL cells that show greater malignancy are more sensitive to the drug than SET2 cells. In the molecular scenario, YM155 modulates apoptosis-, cell cycle-, DNA damage- and autophagy-related genes. Protein expression analysis corroborates the observed cellular phenotype and exploratory gene expression findings. In summary, our results indicate that survivin/BIRC5 and XIAP are differently expressed in myeloproliferative neoplasms and YM155 has multiple antineoplastic effects on JAK2V617F cells suggesting that inhibitor of apoptosis proteins may be a target for pharmacological interventions in the treatment of these diseases.

最近,遗传学和药理学研究进一步证实了控制细胞凋亡在费城染色体阴性骨髓增殖性肿瘤病理生理学中的核心作用。凋亡抑制蛋白家族有 8 个成员,在细胞凋亡中发挥着重要作用,其中研究最多的是存活素(BIRC5)和 X 连锁凋亡抑制因子(XIAP)。YM155 是一种具有抗肿瘤潜力的小分子,被描述为存活素和 XIAP 的抑制剂。在本研究中,与健康供体相比,原发性骨髓纤维化患者的 BIRC5 表达明显增加。另一方面,XIAP在骨髓增生性肿瘤患者中的表达减少。在 JAK2V617F 细胞中,YM155 可降低细胞活力和自主克隆生长,诱导细胞凋亡、细胞周期停滞和自噬。与 SET2 细胞相比,恶性程度更高的 HEL 细胞对该药物更敏感。在分子情景中,YM155 可调节细胞凋亡、细胞周期、DNA 损伤和自噬相关基因。蛋白质表达分析证实了观察到的细胞表型和探索性基因表达发现。总之,我们的研究结果表明,存活素/BIRC5 和 XIAP 在骨髓增生性肿瘤中的表达不同,YM155 对 JAK2V617F 细胞有多种抗肿瘤作用,这表明凋亡抑制蛋白可能是治疗这些疾病的药物干预靶点。
{"title":"The survivin/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2<sup>V617F</sup> cells.","authors":"Jorge Antonio Elias Godoy Carlos, Keli Lima, Eduardo Magalhães Rego, Leticia Veras Costa-Lotufo, João Agostinho Machado-Neto","doi":"10.1016/j.htct.2024.05.012","DOIUrl":"https://doi.org/10.1016/j.htct.2024.05.012","url":null,"abstract":"<p><p>The central role of the control of apoptosis in the pathophysiology of Philadelphia chromosome-negative myeloproliferative neoplasms has recently been reinforced in genetic and pharmacological studies. The inhibitor of apoptosis protein family has eight members and plays an important role in apoptosis, with the most studied being survivin (BIRC5) and X-linked inhibitor of apoptosis (XIAP). YM155 is a small molecule with antineoplastic potential that has been described as a suppressant of survivin and XIAP. In the present study, BIRC5 expression was significantly increased in primary myelofibrosis patients compared to healthy donors. On the other hand, XIAP expression was reduced in myeloproliferative neoplasms patients. In JAK2<sup>V617F</sup> cells, YM155 reduces cell viability and autonomous clonal growth and induces apoptosis, cell cycle arrest, and autophagy. HEL cells that show greater malignancy are more sensitive to the drug than SET2 cells. In the molecular scenario, YM155 modulates apoptosis-, cell cycle-, DNA damage- and autophagy-related genes. Protein expression analysis corroborates the observed cellular phenotype and exploratory gene expression findings. In summary, our results indicate that survivin/BIRC5 and XIAP are differently expressed in myeloproliferative neoplasms and YM155 has multiple antineoplastic effects on JAK2<sup>V617F</sup> cells suggesting that inhibitor of apoptosis proteins may be a target for pharmacological interventions in the treatment of these diseases.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hematology, transfusion and cell therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1